Business Wire·Mar 14, 2023, 5:53 PM ET

Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18

– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib – – Breakthrough Therapy Designation is Based on Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical